Skip to product information
L-carnitine 500mg/ml 10ml vial - RCpeptides
L-carnitine 500mg/ml 10ml vial

L-carnitine 500mg/ml 10ml vial

€20,00 EUR
Taxes included.

                                              NOT FOR HUMAN CONSUMPTION

L-Carnitine is a quaternary amine derived from lysine and methionine that shuttles long-chain fatty acyl-CoAs into mitochondria for β-oxidation via the carnitine shuttle (CPT-I → CACT → CPT-II). It also buffers the acyl-CoA/CoAratio by exporting excess acyl groups as acyl-carnitines, influences peroxisomal FAO, and modulates mitochondrial acetylation by serving as an acetyl sink (acetyl-L-carnitine). Clinically, IV L-carnitine is approved for secondary carnitine deficiency in hemodialysis; oral forms are used as dietary supplements (base, L-carnitine tartrate/LCLT, propionyl-L-carnitine/PLC, and acetyl-L-carnitine/ALCAR).

Additional Benefits of L-Carnitine Now Under Investigation

Benefit Key take-aways
1 Heart failure & ischemia Meta-analyses and trials suggest improvements in LVEF, exercise tolerance, and symptoms with L-carnitine/propionyl-L-carnitine; post-MI cohorts reported signals for arrhythmia/mortality reduction, though evidence is heterogeneous and older. <br/><em>Journal of the American College of Cardiology; Circulation; Nutrition, Metabolism & Cardiovascular Diseases</em>
2 Peripheral arterial disease (PAD) Propionyl-L-carnitine improves pain-free walking distance and claudication metrics in several RCTs. <br/><em>Circulation; American Journal of Cardiology</em>
3 Male infertility Oral L-carnitine ± ALCAR improves sperm motility and morphology with higher spontaneous pregnancy rates in select trials. <br/><em>Fertility and Sterility; Andrology</em>
4 NAFLD/MASH Adjunct L-carnitine reduces ALT/AST, improves insulin resistance, and in some studies lowers hepatic fat on imaging. <br/><em>Hepatology; Liver International</em>
5 Glycaemic control & insulin sensitivity Acute carnitine enhances glucose disposal/fat oxidation during clamps; multi-week studies report modest HbA1c/insulin sensitivity gains (mixed results across phenotypes). <br/><em>Diabetes; Metabolism</em>
6 Exercise performance & recovery Long-term LCLT co-ingested with carbohydrate raises muscle carnitine, shifting fuel use toward fat, reducing glycogen use and perceived exertion; small benefits in repeated-sprint recovery and markers of muscle damage. <br/><em>Journal of Physiology; MSSE; Amino Acids</em>
7 Fatigue syndromes Signals for reduced fatigue in cancer-related fatigue and chronic fatigue cohorts, especially with ALCAR. <br/><em>Journal of Clinical Oncology; CNS Drugs</em>
8 Dialysis-related symptoms In hemodialysis patients, IV/oral L-carnitine can improve intradialytic hypotension, cramps, anemia indices, and QoL in carnitine-deficient states. <br/><em>American Journal of Kidney Diseases; Nephrology Dialysis Transplantation</em>
9 Valproate-associated hyperammonemia/toxicity (adjunct) L-Carnitine is used to treat or prevent valproate-induced hyperammonemia and hepatotoxicity, with improved biochemistry and mental status in case series and protocols. <br/><em>Neurology; Clinical Toxicology</em>

2. Molecular Mechanism of Action

2.1 Target Pharmacodynamics

  • Mitochondrial fatty-acid import: CPT-I converts acyl-CoA→acyl-carnitine (outer membrane) → CACT shuttles across → CPT-II regenerates acyl-CoA in the matrix for β-oxidation.

  • Acyl buffering: Carnitine accepts acyl and acetyl groups (→ acyl/acetyl-carnitines), preserving free CoA for TCA and detoxifying acyl overload.

  • Transporters: Cellular uptake via OCTN2 (SLC22A5); renal OCTN2 mediates reabsorption (mutations cause primary carnitine deficiency).

2.2 Down-stream Biology

Pathway Functional outcome Context
β-oxidation & TCA coupling ↑ Fat oxidation, ↑ ATP, ↓ lipid intermediates (DAG/ceramides) Muscle, heart, liver
Acetyl/CoA buffering Maintains acetyl-CoA:CoA balance; affects mitochondrial protein acetylation Mitochondria
Peroxisomal FAO interfacing Handling of very-long-chain FAs (acyl-carnitine export) Liver, heart
Endothelial/NO signalling (PLC) Improved microvascular flow, PAD walking distance Vasculature
Neuroenergetics (ALCAR) Acetyl donor, neurotransmission support CNS/PNS

3. Pharmacokinetics

  • Absorption: Oral bioavailability ~5–18% at supplemental doses (saturable); from food ~60–75%.

  • Distribution: Highest pools in skeletal muscle and heart; plasma carnitine is a small fraction.

  • Transport/renal: OCTN2 uptake; renal reabsorption saturates—excess is excreted.

  • Half-life: Hours; varies by formulation (LCLT, PLC, ALCAR).

  • Forms & notes: LCLT (sports; rapid plasma rise), ALCAR (BBB-penetrant), PLC (vascular/PAD focus), IV(dialysis deficiency).

4. Pre-clinical and Translational Evidence

4.1 Cardiovascular

In HFrEF and ischemia, carnitine/PLC improved hemodynamics, LVEF, and exercise time; older post-MI data suggested arrhythmia/mortality benefits (methodological heterogeneity warrants caution).

4.2 Metabolic & Hepatic

Trials in NAFLD/T2D show ALT/AST reduction, insulin-sensitivity improvements, and triglyceride lowering; weight-loss effects are small (meta-analyses: ~1–2 kg vs placebo).

4.3 Performance

When muscle carnitine is increased chronically (high-carb co-ingestion + L-carnitine), studies report lower muscle glycolysis, higher fat oxidation, and reduced fatigue during endurance or repeated sprints; acute dosing alone is usually neutral.

4.4 Neurologic & Fatigue

ALCAR shows modest cognitive/mood benefits in aging/depression and neuropathy (including chemo-induced), though not uniformly replicated.

4.5 Renal/Dialysis & Toxicology

IV L-carnitine corrects deficiency and improves dialysis symptoms in selected patients. In valproatetoxicity/hyperammonemia, IV L-carnitine is standard adjunct in many protocols.

Evidence quality note: Robust biochemistry and physiology; clinical effects vary by population, formulation, dose, and co-interventions (e.g., carbohydrate loading for muscle uptake).

5. Emerging Clinical Interests

Field Rationale Current status
MASH/NAFLD Oxidative flux, insulin sensitivity Ongoing RCTs
HFpEF/HFrEF optimization Myocardial FAO support Mixed evidence; modern trials needed
Sarcopenic obesity Fuel partitioning, training synergy Exploratory
Cancer-related fatigue Neuroenergetic support (ALCAR) Small RCTs; mixed
Male infertility Sperm motility/morphology Positive signals; guidelines vary
PAD rehab PLC-mediated microvascular effects Multiple RCTs; not universal practice

6. Safety and Tolerability

  • Common: GI upset, nausea, diarrhea; fishy body odor (trimethylamine).

  • TMAO concern: Chronic high-dose L-carnitine can raise plasma TMAO (microbiome-dependent), a biomarker linked to ASCVD risk—clinical significance under supplementation remains debated.

  • Seizure risk: Rare seizure exacerbation reported in predisposed patients.

  • Drug interactions: May antagonize thyroid hormone actions (historical use in thyrotoxicosis symptoms); separate from levothyroxine dosing if concerned.

  • Special populations: Hemodialysis deficiency merits IV therapy per guidelines; primary carnitine deficiencyrequires specialist care.

  • Typical supplemental ranges: 1–3 g/day oral divided (LCLT/ALCAR/PLC); IV dosing individualized in dialysis or toxicology settings.

Comparative safety matrix

Feature L-Carnitine (base/LCLT) Propionyl-L-carnitine (PLC) Acetyl-L-carnitine (ALCAR)
Primary use Metabolic/fat oxidation; sports PAD/vascular, cardiac ischemia CNS/neuropathy, fatigue
CNS penetration Low Low Higher
Evidence for exercise Chronic + carbs → benefit Limited Mixed
GI/TMAO Moderate; TMAO↑ possible Similar Lower odor; similar TMAO biology

7. Regulatory Landscape

  • Approved: IV L-carnitine for carnitine deficiency in ESRD on dialysis (varies by region).

  • Non-approved (supplement): Oral forms (LCLT, ALCAR, PLC) marketed as dietary supplements—quality varies; seek GMP/third-party testing.

  • Sports: Permitted substance, but beware of adulterated products.

8. Future Directions

  • Phenotype-targeted RCTs in NAFLD/MASH, HFpEF, and insulin-resistant phenotypes with imaging and clamp endpoints.

  • Microbiome-aware protocols to mitigate TMAO (dietary fiber, probiotics, dosing strategies).

  • Muscle uptake optimization (insulin-sensitizing co-interventions) and time-of-day dosing with training.

  • Head-to-head of LCLT vs ALCAR vs PLC for specific outcomes (endurance, cognition, PAD).

  • Metabolomics of acyl-carnitine signatures as biomarkers of response.

Selected References

  • Circulation; JACC; Nutrition, Metabolism & Cardiovascular Diseases — L-/propionyl-L-carnitine in heart failure and ischemia.

  • American Journal of Cardiology; Circulation — Propionyl-L-carnitine improves claudication metrics in PAD.

  • Fertility and Sterility; Andrology — Male infertility trials with L-carnitine ± ALCAR.

  • Hepatology; Liver International — NAFLD/MASH adjunctive therapy signals.

  • Diabetes; Metabolism — Clamp studies on glucose disposal and fat oxidation.

  • Journal of Physiology; Medicine & Science in Sports & Exercise; Amino Acids — Long-term muscle carnitine loading, exercise metabolism, and recovery.

  • American Journal of Kidney Diseases; Nephrology Dialysis Transplantation — Hemodialysis deficiency and IV L-carnitine outcomes.

  • Neurology; Clinical Toxicology — L-carnitine in valproate-induced hyperammonemia/toxicity.

  • Atherosclerosis; European Heart Journal — TMAO biology and cardiovascular risk context.